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ABSTRACT
Zoledronic acid (ZA) is a biphosphonate used for osteoporosis treatment and also 
proved to be effective to reduce the pain induced by bone metastases when used as 
adjuvant therapy in solid cancers. However, it has been recently proposed that ZA could 
have direct anti-tumour effects, although the molecular mechanism is unknown. We 
herein unravel a novel anti-tumour activity of ZA in prostate cancer (PCa), by targeting 
the pro-tumorigenic properties of both stromal and immune cells. Particularly, we 
demonstrate that ZA impairs PCa-induced M2-macrophages polarization, reducing 
their pro-invasive effect on tumour cells and their pro-angiogenic features. Crucially, 
ZA administration reverts cancer associated fibroblasts (CAFs) activation by targeting 
the mevalonate pathway and RhoA geranyl-geranylation, thereby impairing smooth 
muscle actin-α fibers organization, a prerequisite of fibroblast activation. Moreover, ZA 
prevents the M2 macrophages-mediated activation of normal fibroblast, highlighting 
the broad efficacy of this drug on tumour microenvironment. These results are 
confirmed in a metastatic xenograft PCa mouse model in which ZA-induced stromal 
normalization impairs cancer-stromal cells crosstalk, resulting in a significant 
reduction of primary tumour growth and metastases. Overall these findings reinforce 
the efficacy of ZA as a potential therapeutic approach to reduce cancer aggressiveness, 
by abrogating the supportive role of tumour microenvironment.
INTRODUCTION
Inflammation is now acknowledged as a 
hallmark of cancer and several tumour-associated cells 
are active players in promoting a pro-inflammatory 
microenvironment, including cancer associated fibroblasts 
(CAFs) and tumour-associated macrophages (TAMs). 
These accessory cells establish a malignant cross-talk 
with cancer cells that affects the behaviour of each other, 
ultimately allowing cancer to acquire aggressive features 
[1].
CAFs, one of the major components of tumour 
microenvironment, have been reported to induce 
epithelial-to-mesenchymal transition (EMT), invasiveness, 
resistance to anoikis and chemotherapeutic agents, as well 
as stem-like features of cancer cells, thereby contributing 
to metastatic spread [2–4]. CAFs also cooperate with 
tumour cells in fostering de novo angiogenesis [5]. In 
addition, CAFs establish a metabolic cross-talk with 
cancer cells, an acknowledgment prerequisite of highly 
aggressive tumours. Particularly, prostate cancer (PCa) 
cells meet their energetic and anabolic requirements by 
exploiting the lactate produced by glycolysis-dependent 
CAFs [6, 7].
CAFs have also been reported to induce the 
establishment of a pro-inflammatory microenvironment, 
by concurring to monocyte recruitment to tumour site 
and polarization into the pro-tumoral subset of M2 
macrophages in a stromal derived growth factor-1-
dependent manner [8]. In turn, M2 macrophages support 
malignant progression by promoting angiogenesis and the 
establishment of an immunosoppressive microenvironment 
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[9, 10]. In keeping, switch of M1 macrophages, endowed 
with immune stimulating and anti-tumour activities, 
towards the M2 phenotype is associated with a worse 
clinical prognosis and high grade of malignancy [11, 12]. 
Recent studies also demonstrate that M2 macrophages are 
able to modulate stromal reactivity, by inducing fibroblast 
activation [8]. This interplay between CAFs and M2 
macrophages promotes (i) tumour cell motility, hence 
favouring cancer cells to leave the primary tumour site and 
(ii) the activation of both endothelial cells and their bone-
marrow-derived precursors to drive de novo angiogenesis, 
a step that facilitate metastatic dissemination [8].
Zoledronic acid (ZA) is a FDA-approved third-
generation amino-bisphosphonate that has been used 
as adjuvant therapy to reduce skeletal related events 
(SREs) and pain associated with bone metastases in 
several types of cancer, including PCa [13]. Additionally, 
ZA has been found to have a direct anti-tumour 
efficacy. Indeed, ZA inhibits cell proliferation and 
induces apoptosis in human leukemic cell lines [14]. In 
addition, ZA directly target endothelial progenitor cells 
interfering with their differentiation, thus impairing their 
supportive role in cancer cells escape from primary sites 
[15]. More recently, ZA has been shown to improve 
immunesurveillance against tumour and to modulate 
macrophage differentiation, opening new possibilities for 
its therapeutic application [16]. However, the molecular 
mechanisms behind the anti-cancer response of ZA and its 
effects on non-cancerous stromal cells, remains yet largely 
unclear and need to be clarified.
Here, we report that in PCa cellular models ZA 
impairs both M2 macrophages differentiation and CAF 
activation, thus impairing their supportive roles in PCa 
tumour progression. This suggests that the benefit of ZA 
in the therapy of PCa-bearing patients, potentially goes 
beyond the simple skeletal/bone symptoms treatment, but 
is enlarged to regulation of stromal inflammatory events, 
with a consequent impact on cancer cells malignancy.
RESULTS
ZA treatment impairs M2 macrophages 
polarization
We have recently reported that PCa cells recruit 
monocytes and polarize them towards an M2 macrophages 
phenotype, which in turn promote cancer cell invasiveness 
[8]. Since ZA has been proposed to have anti-tumoral and 
immunomodulatory properties [17], we aim at investigating 
the effect of the compound on this feed-forward loop 
between cancer and immune cells. Monocytes isolated 
from normal human blood donors buffy coat were treated 
with macrophage colony-stimulating factor (MCSF) to 
promote differentiation into macrophage, enabling them 
to proliferate and later acquire a specific polarization 
into M1, M2 or M2-like macrophages upon stimulation 
with LPS+IFN-γ, IL-4 or CM from PC3, respectively. 
Of note, treatment to polarize towards a M1, M2 or M2-
like phenotype by means of specific treatment During the 
differentiation period, ZA was administrated at different 
doses (Supplementary Figure S1A).
To analyse if ZA treatment can impact on 
macrophages polarization, we evaluated the production 
of IL-10 and IL-12. Indeed, while M1 macrophages 
are characterized by IL-12high/IL-10low phenotype, M2 
macrophages show an IL-12low/IL-10high production [18]. 
The results demonstrate that treatment with ZA reduces IL-
10 expression without affecting IL-12 levels, suggesting a 
drug-dependent impairment of M2 polarization, without 
a conversion towards the M1 phenotype (Figure 1A-
1B). Notably, ZA appears to be effective at the lower 
dose of 200 nM, without any significant dose-dependent 
effect. To further analyse the M1/M2 subtype modulation 
upon ZA administration, we analysed the expression 
of MCSF receptor (MCSF-R), in order to confirm the 
acquisition of the differentiated phenotype, CD206 as a 
cell surface marker for M2 polarized macrophages and 
cycloxigenase-2 (COX-2) and iNOS as markers for the 
M1 subtype. MCSF-R is highly expressed by macrophages 
cultured with MCSF, as well as by macrophages incubated 
with CM from PC3 or treated with ZA. In contrast, only 
M1 macrophages express high level of COX-2 (Figure 
1C). These data highlight that ZA can reduce the pool 
of pro-tumoral M2-polarized macrophages, without 
promoting a real unbalance towards the anti-tumoral M1-
polarized macrophages.
ZA-treated M2-polarized macrophages 
negatively affect invasiveness of PCa cells
We have reported that M2 and M2-like macrophages 
are able to increase cancer cells malignancy [8]. To 
evaluate the effects of both M2 or M2-like macrophages 
treated with ZA on PC3 cells motility, CM from 
the above-treated macrophages were collected and 
administered to PCa cells for 24h. An invasion assay 
was then performed. In agreement with our previous 
data, M2 and M2-like macrophages elicit a pro-invasive 
effect on PC3 cells, which is significantly impaired by 
ZA administration (Figure 2A-2B). Importantly, PC3 
cell survival was unaffected by ZA treatment, therefore 
excluding an effect on cell viability rather than on cell 
motility (Supplementary Figure S2). These data reveals 
that ZA-dependent inhibition of M2 polarization leads to 
an indirect impairment of tumour cell invasion.
ZA hinders the angiogenic response induced by 
M2 and M2-like macrophages
We demonstrated that M2 macrophages contribute 
to increase tube-like structures formation in EPCs 
and HUVECs, suggesting a key role of immune cells 
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Figure 1: ZA suppresses monocyte differentiation toward M2 macrophages A, B. Human monocytes isolated from normal 
donor buffy coat were cultured for 7 days with M-CSF (50ng/ml). Differentiation toward the M1 phenotype was induced by treatment with 
LPS (100 ng/ml) and IFNγ (100 ng/ml) for 24h. M2 macrophages were polarized by stimulating with IL-4 (20 ng/ml) for 24h. Alternatively, 
M2-like macrophages were obtained by treating isolated monocytes with CM from PC3 for 7 days. During differentiation macrophages 
were treated with different concentrations of ZA and the levels of IL-12 or IL-10 were measured by ELISA test. 1-way ANOVA, Dunnett’s 
corrected, ***p< 0,001 vs untreated. C. Cells treated as in A were lysed and the expression of M-CSFR, COX-2, CD206, NOS2 and actin 
was evaluated by immunoblots.
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in driving tumour vascularization [8]. We therefore 
investigated whether the contact with ZA-treated M2/
M2-like-polarized macrophages, could affect the 
angiogenic features of endothelial cells. We treated 
HUVECs or EPCs with CM from the differently 
treated macrophages and assayed their ability to form 
tube-like structures in vitro. We showed that upon ZA-
treatment there is a significant reduction of capillary-like 
structures assembly, suggesting that the drug, through 
the impairment of M2 polarization, may indirectly 
affect de novo intratumoral angiogenesis (Figure 3 and 
Supplementary Figure S3).
ZA reverts CAF-activated phenotype and their 
pro-invasive features
To investigate the potential effects of ZA on other 
cellular components of tumour microenvironment, we 
focused our interest on stromal fibroblasts, since the 
achievement of aggressive features of cancer cells is 
strongly dependent on their contact with surrounding 
CAFs [2, 3]. Normal fibroblasts (HPFs) and CAFs 
were treated with increasing concentrations of ZA for 
5 days. The evaluation of alpha smooth muscle actin 
(α-SMA) expression, a reported marker of fibroblasts 
Figure 2: M2 and M2-like macrophages-dependent increase of PC3 cells invasiveness is impaired by ZA treatment. 
A. Monocytes were differentiated for 7 days with M-CSF and then polarized into M2 macrophages by stimulating with IL-4 for 24h. 
Alternatively, monocytes were stimulated with CM from PC3 for 7 days to obtain M2-like macrophages. ZA was administrated during 
differentiation at different concentrations and then macrophages were serum-starved for 48h to obtain the corresponding CM. PC3 cells 
were incubated for 24h with CM from the above differentiated macrophages (treated or not with ZA), or serum starved as a control, and 
then allowed to invade toward medium containing 10% serum as chemoattractant for additional 24 h. (St. Med. Starvation Medium) B. 
Invading cells were counted and the mean of six randomly chosen fields was plotted in the bar graph. 1-way ANOVA, Dunnett’s corrected, 
***p< 0,001 vs untreated.
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activation (Figure 4A) and the quantification of 
collagen contractility, an established feature of activated 
fibroblasts (Figure 4B), reveal that ZA administration 
completely reverts the activated phenotype of CAFs. To 
confirm the ZA-dependent conversion of CAFs towards 
a non-activated state, we explored whether ZA-treated 
CAFs were still able to promote cancer cell motility. 
PC3 cells were conditioned with CM obtained from HPF 
and CAF treated as above, and tested for their migratory 
abilities (Supplementary Figure S1B). Crucially, ZA-
treatment abolishes CAF ability to enhance PC3 cell 
invasiveness (Figure 4B-4C). Comparable results were 
obtained with DU145, an additional PCa cell line 
(Supplementary Figure S4).
Figure 3: Treatment with ZA inhibits the M2/M2-like macrophages-induced pro-angiogenic effect. M2 and M2-like 
macrophages were obtained by treating monocytes for 7 days with M-CSF (then treated with IL-4 for additional 24h) or with CM from 
PC3, respectively. M2 and M2-like macrophages were treated with different concentrations of ZA during differentiation and then were 
serum-starved for 48h to obtain the corresponding CM. HUVEC A. and EPC B. cells were treated with CM from the above differentiated 
macrophages (treated or not with ZA) and in vitro angiogenesis was evaluated by capillary morphogenesis assay. The number of joints was 
quantified and plotted in the bar graph. 1-way ANOVA, Dunnett’s corrected, ***p< 0,001 vs untreated.
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These data reveals that ZA impairs CAF activation 
and therefore their supportive role in PCa malignancy.
ZA hinders fibroblast activation through the 
inhibition of RhoA-GTPase activity
It has been reported that ZA inhibits the active 
site of the enzyme farnesyl pyrophosphate synthase in 
the mevalonate pathway, resulting in reduced levels of 
isoprenoids, including farnesyl pyrophosphate (FPP) and 
geranyl-geranyl pyrophosphate (GGPP), required for 
the prenylation of GTPase signalling proteins (i.e. Rac, 
Rho, Cdc42). This lipid modification is essential for the 
small GTPases family to achieve their active state and 
to ensure cytoskeletal rearrangements and dynamic cell 
shape remodelling [19]. To gain insight into the possible 
Figure 4: ZA administration reverts CAF activation and impairs their pro-invasive effects on cancer cells A. Subconfluent 
HPFs and CAFs were serum starved and treated for 5 days with different concentration of ZA. α-SMA was analyzed by immunoblot as 
a marker for fibroblast activation. Actin was used as loading control. B. HPFs and CAFs were treated in serum-free medium with ZA 
200nM for 5 days and after were placed in DMEM supplemented with collagen. Serum-starved HPFs and CAFs were used as control cells. 
Contraction of the collagen discs is expressed as relative collagen area from ST group. 1-way ANOVA, Bonferroni’s corrected***p< 0,001 
vs CAF. C. PC3 cells were incubated for 24 h with CM from HPFs and CAFs treated as in A and then allowed to invade for additional 24 
h toward medium containing 10% serum as chemoattractant. Invading cells were counted and the mean of six randomly chosen fields was 
plotted in the bar graph. 1-way ANOVA, Dunnett’s corrected, ***p< 0,001 vs CM CAF.
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molecular mechanism responsible for ZA-mediated 
reversion of CAFs activated state, we focused on the 
Rho family GTPases and we examined whether ZA was 
able to affect RhoA activity by reducing its geranyl-
geranylation. To evaluate RhoA activity, CAFs were 
treated in the presence or absence of 200nM ZA, the 
lower dose of the drug that is effective in the reversion 
of CAFs activated phenotype, and then a pull-down 
assay of active GTP-bound RhoA was performed. Our 
results indicate that ZA treatment reduces RhoA activity, 
while the exposure to GGPP or to the Rho activator 
calpeptin, concomitantly to ZA administration, restores 
the GTP-bound active state (Figure 5A). In addition, 
analysis of α-SMA expression in our experimental setting 
Figure 5: ZA inhibits RhoA prenylation/activation, thereby abrogating α-SMA organization and CAF activation. A. 
CAFs were treated in serum-free medium with ZA 200nM for 5 days alone or in combination with geranylgeranyl pyrophosphate 20 
μM (ZA+GGPP) or Rho Activator (ZA+RhoAct). Serum-starved HPFs and CAFs were used as control cells. ActiveGTP-bound RhoA 
was quantified by Rhotekin pull-down assay and normalized by total RhoA immunoblot upon densitometric analysis. 1-way ANOVA, 
Bonferroni’s corrected, *p< 0,05 vs HPF, **p< 0,01 vs CAF, ***p< 0,001 vs CAF+ ZA. B-C. Fibroblasts were treated as in A. α-SMA was 
quantified by both immunoblot (B) and confocal microscopy. Bar, 50 μm (C).
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underlines that RhoA signalling is critical for fibroblast 
activation. Indeed, ZA-mediated prevention of RhoA 
activation strongly reduces α-SMA expression, while the 
addition of GGPP or Rho activator avoids α-SMA down-
regulation, thus overcoming ZA-mediated mevalonate 
pathway inhibition (Figure 5B).
To corroborate these data, we also analysed α-SMA 
stress fibers organization by confocal microscopy. While 
ZA-treated cells showed a faint signal with almost no 
stress fibers, GGPP or Rho activator administration 
recovered pronounced α-SMA fibers formation (Figure 
5C), suggesting the role of ZA in impairing RhoA-mediated 
α-SMA organization and stabilization of CAF phenotype.
ZA abrogates macrophage-dependent fibroblast 
activation
We recently demonstrated that M2 macrophages are 
able to activate healthy HPFs into CAFs, endowing them 
with supportive roles for PCa cells [8]. To better clarify the 
possible role of ZA in the complex interdependency among 
the different components of tumour microenvironment, 
we analysed the effects of ZA-treated M2-polarized 
macrophages on fibroblast activation. HPFs were 
incubated with CM from M2 or M2-like-macrophages, 
with or without different concentration of ZA. Fibroblast 
activation was then analysed by the evaluation of α-SMA 
expression (Figure 6A), stress fibers organization (Figure 
6B) and by assessing their pro-invasive effect on PCa 
cells (Figure 6C). As expected, while M2 and M2-like 
macrophages are active in eliciting fibroblast activation 
and enhancement of PC3 invasiveness, the exposure 
to ZA strongly prevents these effects. Therefore, ZA is 
not only capable to revert the activated state of CAFs, 
already engaged with pro-aggressive roles, but it is also 
effective in preventing the M2 macrophages-mediated 
activation of normal fibroblast, thereby strengthening 
the broad inhibitory function of this drug on tumour 
microenvironment.
ZA prevents CAF-induced enhancement of PCa 
cell tumorigenicity and lung colonization in vivo
As previously reported, CAF conditioning improves 
tumour growth in xenograft models and promotes lung 
colonization and metastases formation [2]. According 
to our in vitro results, we aimed to assess whether 
ZA could be able to neutralize the effects induced by 
CAFs on tumour growth and metastatic spread in vivo. 
As previously reported, we used PC3 cells in limiting 
conditions in order to ensure their in vivo growth and 
metastatic spread only when co-injected with CAFs [2, 
3]. In particular, a mixture of CAFs with PC3 cells (2:1 
ratio) was subcutaneously injected into the lateral flanks 
of SCID bg/bg mice. Mice received repeated courses 
of intraperitoneal injection of ZA (100 μg/kg) once a 
week. We observed that subcutaneous tumours of CAFs/
PC3 injected mice showed higher rate of tumour growth 
compared to ZA-treated tumours (Figure 7A). In addition, 
histological examination of lungs of tumour-bearing mice 
revealed the presence of spontaneous micrometastases 
in all the mice injected with the mixture CAFs/PC3. 
Conversely, ZA-treated animals exhibited a significant 
reduction in the number of metastatic areas (Figure 7B).
Comparable results were obtained with DU145 cells 
(Supplementary Figure S5). These data suggest that the 
clinical efficacy of ZA could be ascribed to its ability to 
rebuild a neutral microenvironment which counteracts 
tumour growth and metastatic spread.
DISCUSSION
ZA is a bisphosphonate now approved for use in the 
treatment of cancer-associated bone disease, preventing 
osteoclast-mediated bone breakdown. Indeed, ZA has been 
shown to effectively reduce the risk of skeletal-related 
events in patients with metastatic PCa [20], multiple 
myeloma [21] and breast cancer [20, 22, 23]. ZA has also 
recently been tested as an additive therapeutic for early-
stage breast cancer [24–26].
In addition to its standard application in the 
adjuvant treatment of symptomatic bone metastases, 
several evidence about a direct anti-tumour effect 
of ZA are emerging [27]. It has been reported that 
bisphosphonates possess calcium-chelating properties, 
responsible for the bone-binding properties of these 
compounds. Since the dysregulation of Ca2+ homeostasis 
has been suggested as an important event in driving 
the enhancement of malignant traits, such as cell 
proliferation, migration and invasion [28], as well as 
tumor vascularization [29], the ZA-dependent regulation 
of calcium homeostasis may be responsible, at least in 
part, for its anti-tumor activity. Notably, ZA also attracts 
interest as a potent immunomodulator, which can be 
exploited in cancer immunotherapy. Recently, Coscia 
and colleagues reported that administration of clinically 
compatible doses of ZA is an effective way of targeting 
hyperplastic cells and TAMs by switching the local 
microenvironment from a highly permissive partner to 
a tumour-hostile counterpart in a murine breast cancer 
[16]. The anti-tumour effect of ZA also relies on the 
ability of the drug to impair the mesenchymal stem cells-
induced TAMs recruitment to tumour sites by decreasing 
the expression of monocyte chemotactic protein-1 
(MCP-1), thus resulting in tumour growth inhibition 
[30]. In addition, ZA has been reported to cooperate 
with different chemotherapeutic agents (e.g. docetaxel, 
imatinib, cisplatin) in impairing cancer cells growth 
in vitro or in vivo [31–34].
Although the effects of ZA are clinically well 
known, the molecular mechanism responsible for its effect 
on cancer cells are not yet well elucidated.
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Here, we underscore a role of the compound on 
tumour microenvironment focusing on the profound 
impact exerted by ZA on M2 macrophages and prostate 
CAFs. According to our evidence, we suggest that the 
anti-tumour effect of ZA relies on the direct targeting of 
stromal and immune cells and on the prevention of their 
pro-tumoral skills.
Resident and recruited cells which infiltrate 
prostate tumours engage with cancer cells a complex 
network of relationships that evolve alongside 
Figure 6: ZA counteracts macrophage-dependent fibroblasts activation. A. M2 and M2-like macrophages were obtained by 
treating monocytes for 7 days with M-CSF (then treated with IL-4 for additional 24h) or with CM from PC3, respectively. M2 and M2-like 
macrophages were treated with different concentrations of ZA during differentiation and then were serum-starved for 48h to obtain the 
corresponding CM. Subconfluent HPFs were treated for 24 h with CM from the above differentiated macrophages (treated or not with ZA) 
or with 10 ng/ml TGF-β1 as a positive control, and serum starved for additional 24 h. Fibroblasts were lysed and immunoblots for α-SMA 
and actin were performed. B. M2 and M2-like macrophages were obtained as in A and were treated with ZA 200nM during differentiation 
and then were serum-starved for 48 h to obtain the corresponding CM. Subconfluent HPFs were treated for 24 h with CM from the above 
differentiated macrophages (treated or not with ZA) or with 10 ng/ml TGF-β1 as a positive control, α-SMA was quantified by confocal 
microscopy. Bar, 50 μm. C. PC3 cells were incubated for 24 h with CM from HPFs treated as in A (CM M2 AFs or CM M2-like AFs; AFs: 
Activated fibroblasts) and then allowed to invade for additional 24 h toward medium containing 10% serum as chemoattractant. Invading 
cells were counted and the mean of six randomly chosen fields was plotted in the bar graph. Representative photographs for each sample 
are shown under the corresponding bar. 1-way ANOVA, Dunnett’s corrected, ***p< 0,001 vs untreated.
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malignant progression [35]. Among several cell types 
affecting PCa behaviour and malignancy, CAFs and 
macrophages exert important and overlapping roles 
[35, 36]. Recently, we demonstrated that CAFs and 
TAMs cooperate to promote PCa malignancy. Indeed, 
CAFs promote monocyte trans-differentiation into the 
M2 macrophage phenotype. In turn, this pro-tumoral 
subset of macrophages fosters stromal reactivity, 
by inducing fibroblast activation. This positive loop 
established between immune and stromal components 
is also supported by tumour cells, which participate 
to this cross-talk through secretion of MCP-1 and IL-
6, thereby facilitating both monocyte recruitment and 
again differentiation into M2 macrophages [8].
Figure 7: ZA in vivo administration prevents tumor growth and lung metastatic dissemination. A. A mixture of 1 × 106 
PC3 cells and 0.5×106 CAFs were subcutaneously injected in both the lateral flanks of SCID bg/bg mice. Mice were treated once a 
week with intraperitoneal injection of PBS (control mice) or 100 μg/kg of ZA, for 6 weeks (n=5 per group), starting the treatment 24 
h after cell injection. The volume of the primary tumour for control or ZA-treated mice was reported at different time points. 2-way 
ANOVA, Bonferroni’s corrected ***p<0,001 vs untreated B. Mice were sacrificed after 6 weeks. Lungs were inspected and the number 
of micrometastases were counted and plotted. Representative paraffin-embedded lung tissue sections, stained with hematoxylin/eosin, are 
shown. Student t-test, **p<0,0036 vs PC3+CAF.
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Here, we demonstrate that M2 polarization 
is reversed by ZA treatment, which aborted IL-10 
production, while it is ineffective on the recovery of the 
M1-polarized macrophages. In contrast, recent evidence 
suggest that therapeutic concentrations of ZA affect 
all types of macrophages, reinforcing the idea that the 
anti-metastatic effects of ZA are predominantly caused 
by modulating tumour microenvironment [37]. While 
M1-polarized macrophages are likely to play an anti-
tumoral response, M2-polarized macrophages have been 
associated with a chronic inflammatory response that 
characterizes several highly malignant tumours [12, 38]. 
The ZA-dependent neutralization of M2 pro-tumoral 
activity brings to three main consequences: i) loss of M2 
macrophages mediated enhancement of PCa cell motility; 
ii) reduction of stromal reactivity, due to the failure of M2 
macrophages to trigger fibroblast activation; iii) inhibition 
of endothelial cells organization into capillary-like 
structures, to which cooperate both TAMs and CAFs. The 
overall effect is to counteract cancer cells motile spur as 
well as tumour vascularization, ultimately avoiding cancer 
cell escape from the primary site and preventing metastatic 
dissemination.
Besides the inhibitory effect of ZA on fibroblast 
activation via M2 macrophages neutralization, we also 
highlight a direct function of the drug in reverting the 
already established CAF activated phenotype. Indeed, 
ZA administration impairs α-SMA expression as well as 
its organization in stress fibers, required to enhance cell 
contractility. These ZA-induced effects are mainly due to 
the interference of the drug with the mevalonate-dependent 
isoprenoid metabolism [39]. Indeed, the failure in the post-
translational addition of GGPP to RhoA impairs the correct 
localization and function of the small GTPase, thereby 
affecting actin cytoskeleton remodelling, stress fibers 
formation and ultimately cell contractility. In keeping, 
previous studies showed that inhibition of the mevalonate 
pathway by statins prevents TGF-β-induced myofibroblast 
transdifferentiation in human Tenon fibroblasts interfering 
with Rho signalling [40]. Since re-exposure to GGPP 
rescued ZA-dependent inhibition of a-SMA, both in terms 
of expression and subcellular localization, we propose 
RhoA geranylgeranylation as responsible for the positive 
effect of the mevalonate pathway on the maintenance of 
CAFs active state.
Alterations within the microenvironment in which 
the tumor develops are now recognized to be crucial 
during key steps of tumor progression, making tumor 
microenvironment components attractive candidates for 
therapeutic modulation. Given the tumour-supporting 
function elicited by CAFs and the self-reinforcing 
loop established between cancer and stromal cells to 
promote cancer cell aggressiveness, a strategy aimed 
at suppressing CAF activation could have interesting 
therapeutic implications. It has been recently reported 
that bisphosphonates reduce the rate of breast cancer 
recurrence in bone, according to a meta-analysis of 
randomized trials of bisphosphonates as adjuvant 
therapy for women with early-stage breast cancer. In 
particular, addition of ZA to adjuvant endocrine therapy 
reduced disease recurrence in bone and non-bone sites 
[26]. According to our evidence, a possible explanation 
of the efficacy of ZA could be ascribed to the effect of 
this bisphosphonate on CAF deactivation, through the 
inhibition of RhoA geranyl-geranylation. We speculate 
that ZA-induced stromal neutralization could interfere 
with the supporting role of CAFs in triggering cancer 
cell escaping from primary site. It is conceivable 
that the synergistic effect observed by combining ZA 
administration to conventional adjuvant endocrine 
therapy could rely on the double inhibitory effect on 
cancer cell proliferation (exerted by endocrine therapy) 
and metastatic dissemination (induced by ZA treatment). 
CAF neutralization induced by ZA may also prevent the 
onset of chemoresistance, thereby favoring response to 
conventional therapy.
Other indications strengthen the idea that 
interfering with CAF active state and promoting stromal 
normalization may be a potential antitumor approach. In 
particular, Mitra et al. previously reported that mimicking 
deregulation of miR-31, miR-214 and miR-155 resulted 
in the reversion of ovarian CAFs into normal fibroblasts, 
due to the down-regulation of several chemokines, which 
are known to be important for CAF function [41]. More 
recently, it has been proposed that prolonged exposure 
to hypoxia, through a prolyl hydroxylase domain protein 
2-dependent stabilization of hypoxia-inducible factor-1a, 
counteracts a-SMA expression, ultimately leading to CAF 
deactivation [42].
Our results globally highlight that ZA exerts a 
specific targeting of stromal inflammatory cells, thus 
hindering their direct pro-tumoral effect and their 
mutual activation loop. In particular, we observe that ZA 
neutralizes pro-invasive and pro-angiogenic activity of M2 
macrophages and fascinatingly leads to CAF deactivation, 
thereby strongly reducing cancer malignancy both in vitro 
and in vivo. These findings support ZA efficacy outside 
bone environment and provide an additional evidence of 
ZA as a potential approach to prevent cancer progression 
through abrogating the metastasis-promoting effects of 
tumour microenvironment.
MATERIALS AND METHODS
Materials
Unless specified, all reagents were obtained from 
Sigma. Antibodies against COX-2, MCSF-R and β-Actin 
was from Santa Cruz Biotechnology. TGF-β1, MCSF 
and IL-4 were from Peprotech. Rho Activator CN01 
(calpeptin) was from Cytoskeleton, Inc. PVDF was from 
Millipore and Matrigel and GST-Rhotekin were from BD 
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Biosciences. The ELISA kit for the quantification of IL-
10 and IL-12 was from Invitrogen. ZOMETA (Zoledronic 
acid) was from Novartis.
Cell cultures
Human prostate carcinoma cells (PC3 and 
DU145) and human umbilical vein endothelial cells 
(HUVEC) were obtained and authenticated by PCR/
short tandem repeat (STR) analysis from the European 
Collection of Cell Cultures (ECACC). PC3 cells 
were maintained at 37°C and 5% CO2 in DMEM 
supplemented with 10% fetal bovine serum, while 
HUVEC were cultured on gelatin 1% coated dishes 
in EGM-2 medium (Lonza). Endothelial progenitor 
cells (EPCs) have been isolated from human umbilical 
cord blood as previously described [43, 44]. Human 
prostate fibroblasts (HPFs and CAFs) were isolated 
from surgical explantation after patient informed 
consent in accord with the Ethics Committee of the 
Azienda Ospedaliera Universitaria Careggi. Briefly, 
HPFs and CAFs were extracted from healthy and 
intratumoral regions of prostate of PCa-bearing patients 
with mean Gleason Score 9 (4+5) and clinical stage 
T3. Tissue samples were aseptically obtained from 
patients undergoing radical prostatectomy with final 
pathological examination confirmation of pT3aN0 
disease. Tissues were digested overnight in 1 mg/
ml collagenase I and cells were plated in DMEM 
containing 10% fetal bovine serum [2].
Monocyte isolation and macrophages 
differentiation
Human monocytes were obtained from normal 
donor buffy coat by gradient centrifugation using 
Ficoll (Histopaque-1077). Non-adherent cells were 
removed and purified monocytes were incubated for 
7 days in RPMI 1640 supplemented with 10% FBS 
and 50 ng/ml macrophage-colony stimulating factor 
(M-CSF) to obtain macrophages. M1 macrophages were 
polarized by stimulating overnight with LPS (100 ng/
ml) (Peprotech) and IFNγ (100 ng/ml) (Peprotech). M2 
macrophages were polarized by stimulating overnight 
with interleukin-4 (IL-4) (20 ng/ml) (Peprotech). M2-
like macrophages were obtain by culturing monocytes 
for 7 days in RPMI 1640 10 % FBS with 50% of 
conditioned medium from PCa.
Preparation of conditioned media
Conditioned media (CM) were obtained from 
untreated HPFs, CAFs, macrophages or PCa. Cells 
were grown to sub-confluence, then serum starved and 
incubated for 48h before collection of the CM. CM were 
harvested, clarified by centrifugation, and used freshly.
Cell lysis and western blot analysis
Fibroblasts, PCa cells or macrophages derived 
from our experimental conditions were lysed for 20 
min on ice in 500 μl of RIPA lysis buffer (50 mM 
Tris–HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 
2 mM EGTA, 1 mM sodium orthovanadate, 1 mM 
phenylmethanesulphonyl-fluoride, 10 mg/ml aprotinin, 
10 mg/ml leupeptin). 20 μg of total proteins were 
loaded on SDS–PAGE, separated and transferred onto 
nitrocellulose. The immunoblots were incubated in 3% 
bovine serum albumin, 10 mmol/L Tris–HCl (pH 7.5), 
1 mmol/L EDTA, and 0.1% Tween 20 for 1h at room 
temperature, probed first with specific antibodies and 
then with appropriate secondary antibodies.
In vitro boyden invasion assay
PCa cell invasion was assayed with the Transwell 
system of Costar equipped with 8 μm-pore-size 
polyvinylpyrrolidone- free polycarbonate filters. Migration 
or invasiveness assays are distinguished by the absence 
(migration assay) or the presence (invasiveness assay) 
of a 3D barrier of Matrigel. 50 μg/cm2 of reconstituted 
Matrigel (BD Biosciences) was added to the top chamber, 
allowed to solidify for 1h at 37 °C, and air dried for 16 
h. The Matrigel barrier was rehydratated with 100 μl of 
Dulbecco’s modified Eagle’s medium for 2h at 37 °C prior 
to use. Cells were loaded into the upper compartment (5 
x 104 cells in 200 μl) in serum-deprived growth medium. 
The Matrigel invasion chambers were placed into 24-
well culture dishes containing 500 μl of the different 
CM from monocytes as a chemoattractant. After 24h of 
incubation at 37°C, non-invading cells and the Matrigel 
layer were mechanically removed using cotton swabs, 
and the microporous membrane containing the invaded 
cells was fixed in 96% methanol and stained with Diff-
Quick staining solutions. Chemotaxis was evaluated by 
counting the cells that migrated to the lower surfaces of 
the polycarbonate filters.
Flow cytometer analysis of apoptotic cell death
Cells undergoing apoptosis were assayed by the 
Annexin-V FLUOS Staining Kit (Roche Applied Sciences), 
according to the manufacturer’s instructions. Briefly, 5x105 
PC3 cells were washed with ice-cold PBS and labeled for 
10 min with both FITC-labelled Annexin V and Propidium 
iodide (PI) in 100 ml of binding buffer (HEPES-buffered 
saline solution with 2.5 mM CaCl
2
). Flow cytometry was 
performed using a FACSscan (BD Biosciences, San Jose, 
CA, USA). The analyzer threshold was adjusted on the flow 
cytometer channel to exclude most of the subcellular debris 
to reduce the background noise. The totality of Annexin 
V+/PI- (early apoptotic) and Annexin V+/PI+ cells (late 
apoptotic) were considered apoptotic.
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ELISA
Cytokine production in macrophages supernatants 
were measured by commercially available ELISA Kits 
(IL-10 and IL-12) according to the manufacturer’s 
instructions (Invitrogen KHC0104/ KHC0104).
Tube-like formation assay
All the experiments were performed using growth 
factor-reduced Matrigel at a concentration of 1 mg/mL. 
50 μL of Matrigel were added to each well of a 96-well 
plate and then placed in a humidified incubator at 37°C 
for 30 min. HUVECs and EPCs (2x104 cells/ well) were 
added to the Matrigel-coated plates in a final volume of 
200 μL. The effects on the morphogenesis of endothelial 
cells were recorded after 6h with an inverted microscope 
equipped with CCD optics and a digital analysis system. 
Results were quantified by measuring the joint numbers 
in the field.
Collagen gel contraction assay
1.5 × 105 fibroblasts were embedded in 500 μl of 
DMEM solution containing 1 mg/mL collagen and cast 
into a well of 24-well plate (Corning, Costar). Such 
fibroblasts containing gel was allowed to polymerize at 
37°C for 1h before detaching the gel disc from the wall 
using a sterile tip. Subsequently, 1 ml of serum-free 
DMEM with or without different concentration of ZA 
was added in the different wells. The floating gels were 
incubated at 37°C and 5% CO
2
 for 24h and the gel area 
were then quantified. To determine the degree of collagen 
gel contraction, pictures of the gels were taken and the 
estimated area of each gel (number of pixels) was analyzed 
with Adobe PhotoshopTM.
RhoA activity assay
HPFs or differently treated CAFs were directly lysed 
in RIPA buffer, the lysates were clarified by centrifugation 
and RhoA-GTP were quantified. Briefly, lysates were 
incubated with 10 μg Rhotekin-GST fusion protein (BD 
Biosciences) for 1h at 4°C. RhoA-GTP (on pull-down 
samples) and RhoA total content (on cell lysates) were 
then quantified by immunoblot.
Confocal microscopy
HPFs or differentially treated CAFs were fixed in 
p-formaldehyde (4% v/v in PBS) for 20 min. The cells 
were permeabilized in Triton X-100 (0.5% v/v in PBS) 
for 5 min, and then incubated in horse serum (5% v/v 
PBS) for 30 min, and with primary antibodies against 
α-SMA (mouse monoclonal; 1:100; Sigma-Aldrich), 
overnight at 4°C. After two washing steps with PBS, cells 
were incubated with anti-mouse AlexaFluor 488 (1:1000; 
Molecular Probes) for 1h at RT in the dark. The coverslips 
were mounted in Gel Mount™ Aqueous Mounting 
Medium (Sigma-Aldrich). A Leica SP5 Confocal 
microscope was used for data acquisition. Images were 
generated with Leica SP5 Confocal Software.
Xenograft experiments
In vivo experiments were performed in accordance 
with national guidelines and approved by the ethical 
committee of Animal Welfare Office of Italian Work 
Ministry and conform to the legal mandates and Italian 
guidelines for the care and maintenance of laboratory 
animals. 6- to 8-week-old male severe combined 
immunodeficient (SCID)-bg/bg mice (Charles River 
Laboratories International) were injected s.c. with 
1×106 PC3 cells plus 0.5×106 CAFs, both in the right 
and left lateral flanks. Mice received repeated courses 
of intra-peritoneal saline solution (control mice) or 
100 μg/kg of ZA, once a week for 6 weeks. Animals 
(5 per group) were monitored daily. Tumour size 
was measured every 2 to 3 days by a caliper; tumor 
volumes were determined by the length (L) and the 
width (W): V = (LW2)/2 . Mice were sacrificed after 
6 weeks. Lungs were inspected for metastatic nodules 
by histological analyses.
Histology
Lungs were fixed in 4% (vol/vol) phosphate-
buffered formalin and paraffin embedded. Five 
longitudinal sections of each lung per mice (5 μm thick) 
were mounted on positively charged slides. Tissue 
sections were deparaffinized, re-hydrated and stained 
with hematoxylin-eosin staining. Metastases were counted 
using NIS ELEMENTS_F-2.20 software combined with a 
microscope Nikon Eclipse 50i.
Statistical analysis
Data are presented as mean ± SD from at least three 
independent experiments. Statistical analysis of the data 
was performed using GraphPad Prism and the relevant 
analyses are indicated in the Figure Legends.
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